Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry
- PMID: 28659275
- PMCID: PMC5606007
- DOI: 10.1182/blood-2017-05-782383
Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry
Abstract
Prolonged exposure to thiopurines (eg, mercaptopurine [MP]) is essential for curative therapy in acute lymphoblastic leukemia (ALL), but is also associated with frequent dose-limiting hematopoietic toxicities, which is partly explained by inherited genetic polymorphisms in drug metabolizing enzymes (eg, TPMT). Recently, our group and others identified germ line genetic variants in NUDT15 as another major cause of thiopurine-related myelosuppression, particularly in Asian and Hispanic people. In this article, we describe 3 novel NUDT15 coding variants (p.R34T, p.K35E, and p.G17_V18del) in 5 children with ALL enrolled in frontline protocols in Singapore, Taiwan, and at St. Jude Children's Research Hospital. Patients carrying these variants experienced significant toxicity and reduced tolerance to MP across treatment protocols. Functionally, all 3 variants led to partial to complete loss of NUDT15 nucleotide diphosphatase activity and negatively influenced protein stability. In particular, the p.G17_V18del variant protein showed extremely low thermostability and was completely void of catalytic activity, thus likely to confer a high risk of thiopurine intolerance. This in-frame deletion was only seen in African and European patients, and is the first NUDT15 risk variant identified in non-Asian, non-Hispanic populations. In conclusion, we discovered 3 novel loss-of-function variants in NUDT15 associated with MP toxicity, enabling more comprehensive pharmacogenetics-based thiopurine dose adjustments across diverse populations.
© 2017 by The American Society of Hematology.
Conflict of interest statement
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Figures

Similar articles
-
Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?BMC Cancer. 2018 May 2;18(1):516. doi: 10.1186/s12885-018-4398-2. BMC Cancer. 2018. PMID: 29720126 Free PMC article.
-
Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.J Clin Oncol. 2015 Apr 10;33(11):1235-42. doi: 10.1200/JCO.2014.59.4671. Epub 2015 Jan 26. J Clin Oncol. 2015. PMID: 25624441 Free PMC article. Clinical Trial.
-
NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.Pediatr Blood Cancer. 2017 Jan;64(1):146-150. doi: 10.1002/pbc.26189. Epub 2016 Aug 31. Pediatr Blood Cancer. 2017. PMID: 27577869
-
NUDT15 Pharmacogenetics in Acute Lymphoblastic Leukemia: Synthesizing Progress for Personalized Thiopurine Therapy.Med Sci (Basel). 2025 Aug 5;13(3):112. doi: 10.3390/medsci13030112. Med Sci (Basel). 2025. PMID: 40843735 Free PMC article. Review.
-
Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.J Gastroenterol. 2018 Feb;53(2):172-180. doi: 10.1007/s00535-017-1416-0. Epub 2017 Nov 30. J Gastroenterol. 2018. PMID: 29192347 Free PMC article. Review.
Cited by
-
Homozygote CRIM1 variant is associated with thiopurine-induced neutropenia in leukemic patients with both wildtype NUDT15 and TPMT.J Transl Med. 2020 Jul 1;18(1):265. doi: 10.1186/s12967-020-02416-7. J Transl Med. 2020. PMID: 32611418 Free PMC article.
-
Identification of NUDT15 gene variants in Amazonian Amerindians and admixed individuals from northern Brazil.PLoS One. 2020 Apr 15;15(4):e0231651. doi: 10.1371/journal.pone.0231651. eCollection 2020. PLoS One. 2020. PMID: 32294118 Free PMC article.
-
Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease.Toxics. 2022 Mar 22;10(4):151. doi: 10.3390/toxics10040151. Toxics. 2022. PMID: 35448412 Free PMC article. Review.
-
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.JAMA. 2019 Feb 26;321(8):773-785. doi: 10.1001/jama.2019.0709. JAMA. 2019. PMID: 30806694 Free PMC article.
-
Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy.Clin Pharmacokinet. 2024 Aug;63(8):1089-1109. doi: 10.1007/s40262-024-01393-0. Epub 2024 Jul 20. Clin Pharmacokinet. 2024. PMID: 39031224 Free PMC article.
References
-
- Koren G, Ferrazini G, Sulh H, et al. . Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med. 1990;323(1):17-21. - PubMed
-
- Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93(9):2817-2823. - PubMed
-
- Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2008;8(1):24-36. - PubMed
-
- Vora A, Goulden N, Wade R, et al. . Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013;14(3):199-209. - PubMed
-
- Relling MV, Hancock ML, Rivera GK, et al. . Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91(23):2001-2008. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases